Newsletter | November 17, 2026

11.17.26 -- September 2026 — CDMO Opportunities And Threats Report

SPONSOR

Webinar: Mission Control For Biologics Tech Transfer: Guiding process performance across sites, scales, and bioreactor systems

Tech transfer isn’t just moving a process from one place to another. It’s about ensuring process understanding and control can withstand changes in scale, equipment, sites, and teams. Explore how bioreactor characterization, scale-down models, in-silico modeling, and cross-site collaboration can uncover uncertainty before it becomes manufacturing risk and help protect product quality and timelines. Click here to learn more.

FOCUS ON OUTSOURCING

September 2026 — CDMO Opportunities And Threats Report

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

CDMOs Evolve IT Validation Strategies To Stay Ahead

CDMOs are modernizing IT validation by adopting risk-based, lifecycle approaches, digital tools, and continuous assurance models to improve compliance, efficiency, scalability, and data integrity.

Improving Clinical Translation For ADCs And Immuno-Oncology

When preclinical tumor models fail to reflect clinical reality, promising therapies pay the price. Examine how advanced patient-derived organoids and 3D models improve predictive accuracy.

Improving Stability Through Science-Led OSD Reformulation

A marketed multivitamin tablet spanning a 0.03% to 46% w/w range failed early in accelerated stability testing. Mechanism-led reformulation and a switch to direct compression changed the outcome.

Why ADC Linker Payload Design Is The Real Differentiator In ADC Success

Linker-payload architecture dictates therapeutic efficacy. Explore chemical strategies for balancing drug-to-antibody ratios, minimizing systemic toxicity, and accelerating translational development.

Strategic Approaches On The Path To GMP Manufacture

Tech transfer is a critical opportunity to establish a strategy for process performance qualification, mitigate late-stage obstacles, and streamline the pathway to clinical and commercial production.

De-Risking A Novel Valve Component For Use With Standard Syringe Systems

A novel valve provides dual‑chamber functionality within standard syringes, keeping two liquid drugs separated until injection while reducing development risk through advanced modeling.

Streamline Your Manufacturing With Development And CDMO Compatibility

Though the journey to mAb development begins at lab scale, for clinical trials and commercial distribution, a production process must be streamlined and scalable to 2,000 L production and above.

De-Risking Your Bioconjugate's Path To Clinical Manufacturing

Discover the challenges when moving a bioconjugate candidate from early development to clinic, along with integrated solutions for navigating this growing area of the biopharmaceutical industry.

OUTSOURCING SOLUTIONS

•

Risk-Based Strategies For Optimizing Biologic Transitions - Alcami

•

Sterile Drug Product - Curia

•

End-To-End Drug Product Filling And Packaging - FUJIFILM Biotechnologies

•

Steriles Express: GMP Clinical Batch In 20 Weeks - Thermo Fisher Scientific

•

Rapid Next-Generation Sequencing Services - ElevateBio

•

Capabilities Update August 2026: Cell Line Development - Lonza

•

Real-Time Monitoring, Predictive Analytics - WuXi Biologics

•

Capabilities Update May 2026: Large Molecule - Rentschler Biopharma

•

An Advanced CLD Platform For New Biologics - KBI Biopharma

Connect With Bioprocess Online: